Evidence map›Paper›PMID 32478669›Full record

ArticleEndocrinology, diabetes & metabolism case reports2020

Inhibin A as a tumor marker for primary bilateral macronodular adrenal hyperplasia.

Rachel Wurth, Crystal Kamilaris, Naris Nilubol, Samira M Sadowski, Annabel Berthon, Martha M Quezado, Fabio R Faucz, Constantine A Stratakis, Fady Hannah-Shmouni

Open access · goldAbstract read
In one paragraph

Article in Endocrinology, diabetes & metabolism case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Rachel WurthSection on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Crystal KamilarisSection on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Naris NilubolSurgical Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Samira M SadowskiSurgical Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Annabel BerthonSection on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Martha M QuezadoLaboratory of Pathology Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Fabio R FauczSection on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Constantine A StratakisSection on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Fady Hannah-ShmouniSection on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development.ORCID 0000-0001-6829-6205
Eunice Kennedy Shriver National Institute of Child Health and Human Development · USNational Cancer Institute · USNational Institutes of Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

summaryPrimary bilateral macronodular adrenal hyperplasia (PBMAH) is a rare cause of ACTH-independent Cushing syndrome (CS). This condition is characterized by glucocorticoid and/or mineralocorticoid excess, and is commonly regulated by aberrant G-protein coupled receptor expression may be subclinical, allowing the disease to progress for years undetected. Inhibin A is a glycoprotein hormone and tumor marker produced by certain endocrine glands including the adrenal cortex, which has not been previously investigated as a potential tumor marker for PBMAH. In the present report, serum inhibin A levels were evaluated in three patients with PBMAH before and after adrenalectomy. In all cases, serum inhibin A was elevated preoperatively and subsequently fell within the normal range after adrenalectomy. Additionally, adrenal tissues stained positive for inhibin A. We conclude that serum inhibin A levels may be a potential tumor marker for PBMAH. LEARNING POINTS: PBMAH is a rare cause of CS. PBMAH may have an insidious presentation, allowing the disease to progress for years prior to diagnosis. Inhibin A is a heterodimeric glycoprotein hormone expressed in the gonads and adrenal cortex. Inhibin A serum concentrations are elevated in some patients with PBMAH, suggesting the potential use of this hormone as a tumor marker. Further exploration of serum inhibin A concentration, as it relates to PBMAH disease progression, is warranted to determine if this hormone could serve as an early detection marker and/or predictor of successful surgical treatment.

Indexed as

17-hydroxysteroids*2020ACTHAdrenalAdrenalectomyAdultAmenorrhoeaAprilAsian - KoreanBlack - AfricanCortisolCT scanCushing's syndromeDiabetes mellitus type 1Diabetes mellitus type 2FemaleGeneticsGynaecomastiaHistopathologyHypercortisolaemiaHyperglycaemiaHypogonadismImmunohistochemistryInhibinInhibin A*Macronodular Adrenal HyperplasiaMacronodular hyperplasiaMaleMolecular genetic analysisNovel diagnostic procedureTelangiectasiasUnited StatesUrinary free cortisolWeight gainWhite

Identifiers

PMID32478669
PMCPMC7219132
OpenAlexW3021421596

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.